BIOSIMILARS, PRODUCED USING THE RECOMBINANT DNA TECHNOLOGY

Author: Avdeeva Zh.I.¹, Bondarev V.P.², Merkulov V.A.³, Olefir Yu.V.⁴

Abstract

The review presents materials on the scientific principles underlying the development, preclinical and clinical research, registration and control of the safety of biosimilar medicines produced using genetic engineering techniques. The number of biosimilars used in the clinic, defined as «biosimilars», is steadily increasing. The features of biotechnological preparations are presented, that requires a special approach to assessing the newly developed preparation evidence of similarity with the original (reference) preparation. To ensure the effectiveness and safety of their use, the procedure for registration of such medicines is determined by the regulatory framework governing the requirements for proof of similarity with previously approved biological medicinal products. The data concerning the differences in the nature and scope of studies at the stages of quality assessment, preclinical and clinical development of biosimilar and original drugs are performed. The issues related to extrapolation of clinical trial results and the issues of medicines interchangeability are reported. The modern information on international experience of biosimilar medicines registration, scientific achievements and regulatory requirements concerning evidence of similarity in assessing the quality, effectiveness and safety of biosimilar biotechnological medicines («biosimilars») has been reported.

Key words

References

Biological preparations. Position of the Russian Association of Endocrinologists. Sakharnyy diabet = Diabetes mellitus. 2013. (3). 121–122. [In Russian].

Biosimilars in the EU. Information guide for healthcare professionals. European Medicines Agency; European Commission, 4 August 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf

European Generic Medicines Association. Handbook on biosimilar medicines. http://www.bogin.nl/files/ega_biosmilarshandbook.pdf

Guidance for industry. Quality consideration in demonstrating biosimilarity of a therapeutic protein product to a reference product. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER), April 2015. https://www.fda.gov/downloads/drugs/guidances/ucm291134.pdf

Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). April 2015. https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf

Guidance on virus validation studies. The design, contribution and interpretation of studies validating the inactivation and removal of viruses (EMEA/CHMP/BWP/398498/2005). London, 24 July 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003795.pdf

Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process. Non-clinical and clinical issues (EMEA/CHMP/BMWP/101695/2006). London, 19 July 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003935.pdf

Guideline on development, production, characterization and specifications for monoclonal antibodies and related products. London: European Medicines Agency, 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/08/WC500211640.pdf

Guideline on drug examination. Vol. I. Moscow: Grif i K, 2013. 328 p. [In Russian].

Guideline on good pharmacovigilance practices (GVP). Product- or population-specific considerations iI: Biological medicinal products. EMA/168402/2014. 4 August 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/08/WC500211728.pdf

Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins (EMEA/CHMP/BMWP/14327/2006). London: European Medicines Agency, January 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf

Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use (EMA/CHMP/BMWP/86289/2010). London: European Medicines Agency. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf

Guideline on similar biological medicinal products (CHMP/437/04). London, 30 October 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005). London, 30 October 2005). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (EMEA/CHMP/BWP/49348/2005). London, 22 February 2006.). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) EMEA/CHMP/BWP/247713/2012. London. 22 May 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf

Guidelines for assuring the quality of monoclonal antibodies for use in humans. WHO Expert Committee on Biological Standardization. Forty-second report. Geneva: World Health Organization, 1992 (WHO Technical Report Series, No. 822). http://apps.who.int/iris/bitstream/handle/10665/39431/WHO_TRS_822.pdf;jsessionid=31AA9621285F7E7956C3CE5BE4F60F36?sequence=1

Guidelines for good clinical practice (GCP) for trials on pharmaceutical product. Annex 3 in WHO Expert Committee on Selection and Use of Essential Medicines. Sixth report. Geneva, World Health Organization. 1995 (WHO Technical Report Series, No. 850). http://apps.who.int/medicinedocs/en/d/Jwhozip13e/

Guidelines for the examination of drugs. Vol. III. Moscow: POLIGRAF-PLYuS, 2014. 344 р. [In Russian].

Guidelines for the examination of drugs. Vol. IV. Moscow: POLIGRAF-PLYuS, 2014. 172 p. [In Russian].

Guidelines on evaluation of similar biotherapeutic products (SBPs). Annex 2. WHO Technical Report Series No. 977, 2013. http://apps.who.int/medicinedocs/en/d/Js19941en/

Guidelines on evaluation of similar biotherapeutic products (SBPs). WHO Expert Committee on Biological Standardization. Geneva, World Health Organization, 19 to 23 October 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf

Guidelines on the quality, safety, and efficacy of biotherapeutic protein products prepared by recombinant DNA technology. Replacement of Annex 3 of WHO Technical Report Series. No. 814. WHO Expert Committee on biological Standardization, October 2013. http://www.who.int/biologicals/biotherapeutics/rDNA_DB_final_19_Nov_2013.pdf

ICH E6 guideline. Guideline for good clinical practice. Geneva, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1996. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf

ICH Q2A guideline. Validation of analytical procedures. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1994. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf

ICH Q2B guideline. Validation of analytical procedures: Methodology. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1996. https://www.fda.gov/downloads/drugs/guidances/ucm073384.pdf

ICH Q5A (R1) guideline. Quality of biotechnological products: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Geneva, 1999. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073454.pdf

ICH Q5E. Comparability of biotechnological/biological products subject to changes in their manufacturing process. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 18 November 2004. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf

ICH Q6B guideline. Note For Guidance on Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (CPMP/ICH/365/96). September 1999. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002824.pdf.

Note for guidance on virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95). London, 14 February 1996. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003684.pdf

Shangin I.V., Smirnov A.S., Schneider A.A. Interchangeability of medicines in Russia: issues and perspectives. Sovremennaya organizatsiya lekarstvennogo obespecheniya = Current Drug Supply Management. 2014. (3). 10–18. [In Russian].

Soldatov A.A., Avdeeva Zh.I., Olefir Yu.V., Merkulov V.A., Bondarev V.P. The safety of biological preparations. Part 2. Safety issues of biosimilars. BIOpreparaty. Profilaktika, diagnostika, lecheniye = BIOpreparations. Prevention, Diagnosis, Treatment. 2016. 16. (2). 78-89. [In Russian].

The impact of biosimilar сompetition. IMS Health, June 2016. http://www.medicinesforeurope.com/wp-content/uploads/2016/08/IMS-Impact-of-Biosimilar-Competition-2016.pdf

Vasilenko I.A. Interchangeability of medicines: comparative aspects. Razrabotka i registratsiya lekarstvennykh sredstv = Drug Development and Registration. 2014. (1). 162–169. [In Russian].

Weise M., Kurki P., Wolff-Holz E., Bielsky M-Ch., Schneider Ch. Biosimilars: the science of extrapolation // Blood. 2014. 124. (22). 3191-3196.

About Authors (Correspondence):

Avdeeva Zh.I. – doctor of medical sciences, professor, chief expert of office for allergen expertise, cytokines and other immunomodulators of center for examination and control of medical immunobiological preparations

Full Text

snmzh_3-2018_avdeeva_i_dr.pdf

Received: 27/06/2018

Accepted: 27/06/2018